Summary
The availability of a vast array of recombinant and synthetic IMMUNOMODULATORS is a significant milestone toward the development of effective therapies for infectious diseases. This is evinced by licensing of several recombinant human CYTOKINES, including COLONY-STIMULATING FACTORS, INTERLEUKINS, INTERFERONS and erythropoietin, for clinical use in patients. Diverse combinations with INTERFERONS and other CYTOKINES for the treatment of various infections have been proposed. Others, including various CHEMOKINES, synthetic CpG oligodeoxynucleotides and glucans, are extensively being investigated in clinical and preclinical studies. Considerable advances have been made on compounds exhibiting CYTOKINE inhibitory properties useful for new treatments of infectious and inflammatory diseases. Many of the major developments and current trends are highlighted in this review. Novel strategies based on the engineering of CYTOKINES and inhibitors are poised to revolutionize therapeutic options contingent upon scientific evidence rather than dictates of discursive empiricism in the coming decades.
Chapter PDF
Keywords
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Infection
- Human Papilloma Virus
- West Nile Virus
- Severe Acute Respiratory Syndrome
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Ksiazek TG, Erdman D, Goldsmith C, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 1953–1966
Taylor PW, Stapleton PD, Paul LJ (2002) New ways to treat bacterial infections. Drug Discov Today 7:1086–1091
Amyes SGB (2000) The rise in bacterial resistance is partly because there have been no new classes of antibiotics since the 1960s. Br Med J 320: 199–200
Hengel H, Masihi KN (2003) Combinatorial immunotherapies for infectious diseases. Int Immunopharmacol 3: 1159–1167
Masihi KN (2003) Concepts of immunostimulation to increase antiparasitic drug action. Parasitol Res 90(Suppl 2): S97–S104
Masihi KN (2001) Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 1: 641–653
Koliouskas D, Sidiropoulos I, Masmanidou M, Dokas S, Ziakas A (2002) Comparative analysis of Peg-interferon alpha-2b and lamivudine in the treatment of chronic hepatitis B patients: preliminary results. J Hepatol 36:237–238
Santantonio T, Anna N, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G (2002) Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 36: 799–804
Billich A (2002) Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs 3: 698–707
Sugahara S, Ichida T, Yamagiwa S, Ishikawa T, Uehara K, Yoshida Y, Yang XH, Nomoto M, Watanabe H, Abo T et al (2002) Thymosin-[alpha]1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res 24: 346–354
Pimstone NR, Canio JB, Chiang MH (2001) Ribavirin/interferon-2b therapy is very effective in the treatment of chronic hepatitis C genotype 2 and 3 patients who have failed to respond virologically to IFN monotherapy. Gastroenterology 120: A-382
Luxon BA, Grace M, Brassard D, Bordens R (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 24: 1363–1383
Rajender R, Modi MW, Pedder S (2002) Use of peginterferon alfa-2a (40 KD) (Pegasys(R)) for the treatment of hepatitis C. Adv Drug Deliv Rev 54: 571–586
Welch W, Foote M (1999) The use of Filgrastim in AIDSrelated neutropenia. J Hematother Stem Cell Res 8(Suppl 1): S9–S16
Kuritzkes DR (1999) Clinical experience with Filgrastim in AIDS. J Hematother Stem Cell Res 8(Suppl 1): S17–S19
Dubreuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R, Gharakhanian S, Rozenbaum W; GCS 309 European Study Group (2000): Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 65: 337–343
Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ (1998) The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 26: 1270–1278
Masihi KN (2003) Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases. Expert Opin Ther Patents 13: 867–882
Pett SL, Emery S (2001) Immunomodulators as adjunctive therapy for HIV-1 infection. J Clin Virol 22: 289–295
David D, Nait-Ighil L, Dupont B, Maral J, Gachot B, Theze J (2001) Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis 183: 730–735
Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF (2002) Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 55: 209–225
Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM et al (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661–666
Dragic T (2001) An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 82: 1807–1814
Lehner T (2002) The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 23: 347–351
Nansen A, Christensen JP, Andreasen SO, Bartholdy C, Christensen JE, Thomsen AR (2002) The role of CC chemokine receptor 5 in antiviral immunity. Blood 99: 1237–1245
Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955–1958
Blanpain C, Libert F, Vassart G, Parmentier M (2002) CCR5 and HIV infection. Receptors Channels 8: 19–31
Lusso P (2002) HIV and chemokines: implications for therapy and vaccine. Vaccine 20: 1964–1967
Scozzafava A, Mastrolorenzo A, Supuran CT (2002) Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem 17: 69–76
Verani A, Lusso P (2002) Chemokines as natural HIV antagonists. Curr Mol Med 2: 691–702
Onuffer JJ, Horuk R (2002) Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci 23: 459–467
Regoes RR, Bonhoeffer SEBA (2002) HIV coreceptor usage and drug treatment. J Theor Biol 217: 443–457
Polo S, Nardese V, De Santis C, Arcelloni C, Paroni R, Sironi F, Verani A, Rizzi M, Bolognesi M, Lusso P (2000) Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR activation. Eur J Immunol 30: 3190–3198
Stanley MA (2002): Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27: 571–577
Krieg AM, Davis HL (2001) Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3: 15–24
Lehrer RI, Ganz T (2002) Defensins of vertebrate animals. Curr Opin Immunol 14: 96–102
Raj PA, Dentino AR (2002) Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 206: 9–18
Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ et al (2002) Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298: 995–1000
Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, Zack JA, Waring AJ, Yang OO, Lehrer RI (2002) Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 99: 1813–1818
Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW (2002) DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100: 1153–1159
Masihi KN, Hadden JW (2002) Protection by methyl inosine monophosphate (MIMP) against aerosol influenza virus infection in mice. Int Immunopharmacol 2: 835–841
Bahr GM (2003) Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. J Antimicrob Chemother 51: 5–8
Mombelli B, Gismondo M (2000) The use of probiotics in medical practice. Int J Antimicrob Agents 16: 531–536
Cross ML (2002) Microbes versus microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens. FEMS Immunol Med Microbiol 34: 245–253
Yasui H, Shida K, Matsuzaki T, Yokokura T (1999) Immunomodulatory function of lactic acid bacteria. Antonie Van Leeuwenhoek 76: 383–389
Hessle C, Hanson LÅ, Wold AE (1999) Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol 116: 276–282
Grevers G, Palacios OA, Rodriguez B, Abel S, van Aubel A (2000) Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open, prospective, multinational study. Adv Ther 17: 103–116
Tielemans C, Gastaldello K, Husson C, Marchant A, Delville JP, Vanherweghem JL, Goldman M (1999) Efficacy of oral immunotherapy on respiratory infections in hemodialysis patients: a double-blind, placebo-controlled study. Clin Nephrol 51: 153–160
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag
About this chapter
Cite this chapter
Masihi, K.N. (2005). Anti-infective activity of immunomodulators. In: Nijkamp, F.P., Parnham, M.J. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7408-X_21
Download citation
DOI: https://doi.org/10.1007/3-7643-7408-X_21
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-5804-4
Online ISBN: 978-3-7643-7408-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)